A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.
Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM.
Tzimopoulou S, et al. Among authors: matthews pm, matthews jc.
J Alzheimers Dis. 2010;22(4):1241-56. doi: 10.3233/JAD-2010-100939.
J Alzheimers Dis. 2010.
PMID: 20930300
Clinical Trial.